Skip to content

User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)

User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03730480
Enrollment
372
Registered
2018-11-05
Start date
2018-09-06
Completion date
2018-10-31
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

This study will collect lay user (subjects) and healthcare professional information on the performance of two different blood glucose monitors, the CONTOUR NEXT and the CONTOUR TV3, in people with and without diabetes. Each subject will use both meters, at different times and in different order, using a fingerstick(s) to collect meter samples. Meter results will be compared to standardized test system to assess the accuracy of the meters' results. Additionally, a blood sample will be drawn from the subject's arm by a trained healthcare professional for testing on both BGMS. Subjects will also be asked to complete a questionnaire to rate their experience using the meters and to evaluate the meter's Instructions for Use. After all testing and the first questionnaire have been completed, the study staff will demonstrate only to subjects with diabetes several features of the meters that would not necessarily be experienced during the meter testing. These subjects will then answer questions about the features in a second questionnaire.

Detailed description

This clinical trial will assess the performance (accuracy) of the CONTOUR NEXT and the CONTOUR TV3 monitoring systems (BGMS) by lay users enrolled as subjects in the study, and by health care professionals. According to a randomization schedule, subjects will be assigned to use either the CONTOUR NEXT or CONTOUR TV3 meters first and then switch and use the second meter, performing the same testing with both meters. They will learn to use the assigned meter by reading the corresponding User Guide (UG) and Quick Reference Guide (QRG). Each subject will perform one fingerstick self-test a palm (AST) test and the study staff will perform a fingerstick test on the subject. All subject self-test results and study staff results will be compared to results from the reference analyzer from a deeper fingerstick. Hematocrit will be measured for all subjects. After testing, all subjects will then complete a questionnaire (Questionnaire 1) to provide feedback on the meter system and instructions for use (UG and QRG). Subjects with diabetes will also have their glucose tested via venipuncture. After all testing is completed on these subjects, the study staff will demonstrate several features of the meter system that would not necessarily be experienced during the brief accuracy testing. These subjects with diabetes will be given a second questionnaire (Questionnaire 2) to provide feedback about the new features of the system. After completing the study procedures for one BGMS, all subjects will then repeat all of these procedures using the second BGMS, except the hematocrit and venipuncture procedures.

Interventions

DEVICEContour Next and Contour TV3 BGMS testing by subjects with and without Diabetes

Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.

Sponsors

Regulatory and Clinical Research Institute Inc
CollaboratorOTHER
Ascensia Diabetes Care
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Males and females, 18 years of age and older * Ability to speak, read and understand English. Subjects must demonstrate ability to read a paragraph from the first page of the User Guide to qualify for the study. * Willing to complete all study procedures.

Exclusion criteria

* Hemophilia or any other bleeding disorder. * Pregnancy (self-reported). * Physical, visual or neurological impairments that would make the person unable to perform testing with the BGMS. * Previous participation in a blood glucose monitoring study using the Ascensia CONTOUR NEXT or CONTOUR TV3 BGMS. * Working for a medical laboratory, hospital or other clinical setting that involves training on or clinical use of blood glucose monitors. * Working for a competitive medical device company, or having an immediate family member or someone who is not a family member but is living within the household of someone who works for such a company. * A condition, which in the opinion of the investigator or designee, would put the person or study conduct at risk.

Design outcomes

Primary

MeasureTime frameDescription
Fingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference Analyzer1 dayNumber of Participants with self fingerstick results from the Contour Next BGMS and Contour TV3 BGMS that are within 15% of results from the Reference Analyzer. Results from the two meter systems will not be compared to each other.

Secondary

MeasureTime frameDescription
Subjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMS1 dayA questionnaire was given to participants with 8 statements about the BGMS instructions for use and ease of use of the meter system. These statements were rated by subjects on a Likert Scale with ratings of 1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree. Participants reporting ratings greater than or equal to 3 are reported. The statements are: 1. I find it easy to do a fingerstick blood test with this meter. 2. The meter display is easy to see and read. 3. It was easy to understand my test results. 4. I like the overall meter design. 5. I find the meter easy to use. 6. The instructions (User Guide and Quick Reference Guide) were easy to understand. 7. The instructions clearly explain how to run a test. 8. The instructions clearly explain what to do if an error message is displayed by the meter. Note that results from the two meter systems will not be compared to each other.

Countries

United States

Participant flow

Recruitment details

Persons with and without diabetes were enrolled in the study from September 06, 2018 to October 31, 2018. These subjects had one visit to the clinical trial center for the study.

Pre-assignment details

No pre assignment

Participants by arm

ArmCount
Contour Next BGMS and Contour TV3 BGMS -Subjects With and Without Diabetes
All subjects test CONTOUR NEXT and Contour TV3 BGMS. Contour Next BGMS testing by subjects with and without Diabetes: All subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Contour TV3 BGMS testing by subjects with and without Diabetes: All subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Subjects with diabetes get a venipuncture and staff tests the venous blood with both BGMS.
372
Total372

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyMeter displayed a HI result which is non evaluable.1

Baseline characteristics

CharacteristicContour Next BGMS and Contour TV3 BGMS -Subjects With and Without Diabetes
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
76 Participants
Age, Categorical
Between 18 and 65 years
295 Participants
Age, Continuous
mean age
53.1 years
STANDARD_DEVIATION 14.86
Ethnicity (NIH/OMB)
Hispanic or Latino
49 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
323 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Sex: Female, Male
Female
206 Participants
Sex: Female, Male
Male
166 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 372
other
Total, other adverse events
2 / 372
serious
Total, serious adverse events
0 / 372

Outcome results

Primary

Fingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference Analyzer

Number of Participants with self fingerstick results from the Contour Next BGMS and Contour TV3 BGMS that are within 15% of results from the Reference Analyzer. Results from the two meter systems will not be compared to each other.

Time frame: 1 day

Population: Number of fingerstick self test results from Contour Next BGMS and Contour TV3 BGMS that are within 15% of reference analyzer results.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Contour Next and Contour TV3 -Subjects With and Without DiabetesFingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference AnalyzerContour Next Contour Next BGMS366 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesFingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference AnalyzerContour TV3 BGMS360 Participants
Comparison: count of number of responses
Secondary

Subjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMS

A questionnaire was given to participants with 8 statements about the BGMS instructions for use and ease of use of the meter system. These statements were rated by subjects on a Likert Scale with ratings of 1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree. Participants reporting ratings greater than or equal to 3 are reported. The statements are: 1. I find it easy to do a fingerstick blood test with this meter. 2. The meter display is easy to see and read. 3. It was easy to understand my test results. 4. I like the overall meter design. 5. I find the meter easy to use. 6. The instructions (User Guide and Quick Reference Guide) were easy to understand. 7. The instructions clearly explain how to run a test. 8. The instructions clearly explain what to do if an error message is displayed by the meter. Note that results from the two meter systems will not be compared to each other.

Time frame: 1 day

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour Next: Responses greater than or equal to 3 for Statement 1371 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour Next: Responses greater than or equal to 3 for Statement 2371 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour Next: Responses greater than or equal to 3 for Statement 3370 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour Next: Responses greater than or equal to 3 for Statement 4359 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour Next: Responses greater than or equal to 3 for Statement 5371 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour Next: Responses greater than or equal to 3 for Statement 6367 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour Next: Responses greater than or equal to 3 for Statement 7368 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour Next: Responses greater than or equal to 3 for Statement 8368 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour TV3: Responses greater than or equal to 3 for Statement 1369 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour TV3: Responses greater than or equal to 3 for Statement 2370 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour TV3: Responses greater than or equal to 3 for Statement 3369 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour TV3: Responses greater than or equal to 3 for Statement 4353 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour TV3: Responses greater than or equal to 3 for Statement 5370 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour TV3: Responses greater than or equal to 3 for Statement 6369 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour TV3: Responses greater than or equal to 3 for Statement 7370 Participants
Contour Next and Contour TV3 -Subjects With and Without DiabetesSubjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMSContour TV3: Responses greater than or equal to 3 for Statement 8368 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026